KIORA PHARMACEUTICALS INC - 10-Q Filing

Kiora Pharmaceuticals reports Q3 2026 financial results featuring significant R&D and G&A expenses alongside collaborative arrangement activity.

SEC EDGAR ·

Tickers: $KPRX

Read the full article at SEC EDGAR

More Regulatory news